Defining drug/drug class refractoriness vs lines of therapy in relapsed/refractory multiple myeloma-Reference-Cited by-同舟云学术

Defining drug/drug class refractoriness vs lines of therapy in relapsed/refractory multiple myeloma

Published:2023-01-11 Issue:1 Volume:13 Page:
ISSN:2044-5385
Container-title:Blood Cancer Journal
language:en
Short-container-title:Blood Cancer J.

Author:

Goel Utkarsh,Charalampous Charalampos,Kapoor Prashant^ORCID,Binder Moritz^ORCID,Buadi Francis K.^ORCID,Dingli David^ORCID,Dispenzieri Angela^ORCID,Fonder Amie,Gertz Morie A.^ORCID,Gonsalves Wilson I.,Hayman Suzanne R.,Hobbs Miriam A.,Hwa Yi L.,Kourelis Taxiarchis^ORCID,Lacy Martha Q.,Leung Nelson,Lin Yi^ORCID,Warsame Rahma M.,Kyle Robert A.,Rajkumar S. Vincent^ORCID,Kumar Shaji K.^ORCID

Publisher

Springer Science and Business Media LLC

Subject

Oncology,Hematology

Link

https://www.nature.com/articles/s41408-023-00785-y.pdf

Reference15 articles.

1. Rajkumar SV, Richardson P, San Miguel JF. Guidelines for determination of the number of prior lines of therapy in multiple myeloma. Blood. 2015;126:921–2.

2. San-Miguel JF, Hungria VT, Yoon SS, Beksac M, Dimopoulos MA, Elghandour A, et al. Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial. Lancet Oncol. 2014;15:1195–206.

3. Moreau P, Joshua D, Chng WJ, Palumbo A, Goldschmidt H, Hájek R, et al. Impact of prior treatment on patients with relapsed multiple myeloma treated with carfilzomib and dexamethasone vs bortezomib and dexamethasone in the phase 3 ENDEAVOR study. Leukemia. 2017;31:115–22.

4. Dimopoulos MA, Moreau P, Palumbo A, Joshua D, Pour L, Hájek R, et al. Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study. Lancet Oncol. 2016;17:27–38.

5. Laubach JP, Schjesvold F, Mariz M, Dimopoulos MA, Lech-Maranda E, Spicka I, et al. Efficacy and safety of oral panobinostat plus subcutaneous bortezomib and oral dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma (PANORAMA 3): an open-label, randomised, phase 2 study. Lancet Oncol. 2021;22:142–54.

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The first case of multiple myeloma treated with ASCT followed by Anti-BCMA CAR-T cells using retrovirus vector: A case report;Heliyon;2024-09

2. Assessment of algorithms for identifying patients with triple-class refractory multiple myeloma using real-world data;Current Medical Research and Opinion;2024-04-12

3. Subsequent therapy and outcomes in patients with newly diagnosed multiple myeloma experiencing disease progression after quadruplet combinations;British Journal of Haematology;2024-01-30

4. The First Case of Multiple Myeloma Treated With ASCT followed by Anti-BCMA CART Cells using Retroviral Vector;2024-01-19

5. Continuous Elotuzumab, Pomalidomide, and Dexamethasone Maintenance Following Second Autologous Transplantation for Multiple Myeloma: Results of a Prospective Phase 2 Multicenter Trial;Transplantation and Cellular Therapy;2023-12